Linda Buck
Adult Health · Los Angeles, CANPI 1063818912
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $106,362 of the $169,846 with a category attached, or 62.6%. AstraZeneca accounts for 61.4% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2023 at $51,846 and has fallen 99.2% since, to $391 in 2025. Among adult health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 396 payments — averaging $428.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$104K
- Daiichi Sankyo Inc.$40K
- Stemline Therapeutics Inc.$17K
- Gilead$6K
- GSK$667
- Incyte Corporation$539
- plus $2K from 25 others
What the payments were for
- Consulting fees$5,3553%
- Speaking & faculty fees$106,36263%
- Travel & lodging$45,50027%
- Food & beverage$12,6287%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 196 | $104,259 |
| Daiichi Sankyo Inc. | 104 | $39,699 |
| Stemline Therapeutics Inc. | 34 | $16,782 |
| Gilead | 17 | $5,795 |
| GSK | 3 | $667 |
| Incyte Corporation | 6 | $539 |
| Seagen Inc. | 4 | $345 |
| Johnson & Johnson | 4 | $200 |
| Karyopharm Therapeutics Inc. | 2 | $186 |
| Pharmaessentia USA Corporation | 2 | $168 |
| Bristol Myers Squibb | 2 | $128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Myriad Genetic Laboratories, Inc. | 1 | $125 |
| Deciphera Pharmaceuticals Inc. | 1 | $121 |
| Lilly USA, LLC | 1 | $110 |
| Aadi Bioscience, Inc. | 1 | $104 |
| Coherus Oncology, Inc. | 1 | $75 |
| Beigene USA, Inc. | 2 | $68 |
| Sun Pharmaceutical Industries Inc. | 1 | $40 |
| Merck | 2 | $38 |
| Immunogen, Inc. | 1 | $38 |
| Regeneron Healthcare Solutions, Inc. | 1 | $37 |
| Novartis | 1 | $30 |
| Blueprint Medicines Corporation | 1 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Myovant Sciences Inc. | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Pfizer | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$169,846 in reported general payments places this provider in the 95th percentile of 785 adult health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 11 | $10,335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $200 | $10,33511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 785 adult health providers in California.
Other adult health in Los Angeles
- Karolina FaysmanLos Angeles$1.1M
- Lisa HinemanLos Angeles$29K
- Tammy HarperLos Angeles$11K
- Jennifer LettsomeLos Angeles$6K
- Melissa LeeLos Angeles$5K
- Jamie YoonLos Angeles$5K
- Naomi PesynaAnaheim$141K
- Stacy GrissenEncinitas$82K
- Kimberly PodsadaSan Diego$78K
- Brenda PatrickSan Leandro$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.